LMDX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	120.55M
Vidutinė apimtis	0.00
Rinkos kapitalizacija	249.63M
EPS	$0 ( 2024-03-19 )
Kita pelno data	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.0140 (93.33%)

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: -0.37 (neutral)

Signal:(34.365) Neutral

LumiraDx Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
OZK	0.892
DDIV	0.888
PNFP	0.881
FTXO	0.88
PSCF	0.879
COLB	0.879
FITB	0.877
UG	0.877
ARQT	0.874
AIRG	0.87

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

LumiraDx Limited Koreliacija - Valiuta/Žaliavos

0.12
( neutral )

-0.01
( neutral )

-0.61
( weak negative )

-0.47
( neutral )

-0.70
( moderate negative )

0.09
( neutral )

LumiraDx Limited Finansinės ataskaitos

Annual	2022
Pajamos:	$254.48M
Bruto pelnas:	$-35.30M (-13.87 %)
EPS:	$-1.590

FY	2022
Pajamos:	$254.48M
Bruto pelnas:	$-35.30M (-13.87 %)
EPS:	$-1.590

Financial Reports:

No articles found.

LumiraDx Limited

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.